YOU want to gain in efficiency in your screening

Relevant models are crucial for multi-target and multicellular diseases (e.g. cancer and neurodegenerative diseases).

WE believe in phenotypic screening as the answer

Because phenotypic screening is a global approach on cells and is performed by High Content Screening (HCS)

HCS Pharma is YOUR partner to implement HCS in your drug discovery

According to your needs, we support you or do it for you!

Services

Explain us your requirements and we develop your assays to best meet your needs !

More
Our vision of the future of laboratories at Forum LABO 2017 Paris

Team

Want to know who we are ?

More
Our vision of the future of laboratories at Forum LABO 2017 Paris

Why HCS ?

To target complex diseases (as cancer and neurodegenerative diseases), more than one target are needed and screening on complex model is recommended.

More
Our vision of the future of laboratories at Forum LABO 2017 Paris

Contact Us

A question ? A comment ? Feel free to contact us !

More
Our vision of the future of laboratories at Forum LABO 2017 Paris

Our Services

Latest Post

+english

07th Apr 2017

More

Our vision of the future of laboratories at Forum LABO 2017 Paris

Deep Learning, Augmented and Virtual Realities could change the laboratory

+english

03rd Apr 2017

More

HCS Pharma at in-cosmetics Global in London

Julian, our COO, will attend in-cosmetics Global in London

+english

31st Mar 2017

More

Poster – In vitro dermocosmetology : high content analysis approach using human primary keratinocytes and fibroblasts

Our poster

+francais

30th Mar 2017

More

Création du label « France HealthTech »

France eHealthTech est un label du ministère français des affaires étrangères

+english

28th Mar 2017

More

DNA typos might be the main cause of genetic mutations occurs in cancer

A controversial study about links between tumors and genetic mutations

+english

20th Mar 2017

More

Elrigfr congres at ForumLabo : We will talk about the future of laboratories !

We will talk about the future of laboratories

+english

16th Mar 2017

More

How phenotypic screening could help to predict DILI ?

HCS/HCA is a great way to predict drugs toxicity

Hemarina relève 8 millions d’euros pour préserver les greffons

HEMO2life en voie de commercialisation

+english

16th Mar 2017

More

Meet us at the first DYRK conference in Saint Malo, march 28th to April 1st

The conference will focus on DYRK1A, DYRK1B, 2, 3, 4 and the closely related CLKs

+english

13th Mar 2017

More

We are hiring laboratory technicians

You want to join our teams in Rennes and in Lille ?

+english

10th Mar 2017

More

Phenotypic characterization on liver spheroïds

3D cell models are now attracting a huge interest from scientists working both on toxicity and pharmacology assay development....

+english

02nd Mar 2017

More

We are hiring a study director in Rennes !

Study Director position opens in Rennes

+english

02nd Mar 2017

More

We are hiring a business developer in Lille !

A position in open is Lille !

+english

27th Feb 2017

More

Comparing high content screening results

High Content - Less Mess, More Mesh

+english

21st Feb 2017

More

A live cell imaging of phagocytosis and endocytosis

Using live cell staining, we set up a kinetic acquisation of fluorescent active phagosomes.

+english

07th Feb 2017

More

Anthony will work on microenvironment modifications in hepatocarcinoma

Welcome Anthony !

+english

02nd Feb 2017

More

The Most Exciting Medical Technologies of 2017 for The Medical Futurist

At HCS Pharma, we work on many of the most exiting medical technologies !

+english

26th Jan 2017

More

Machine Vision Helps Spot New Drug Treatments

From amazing amount of data to potential treatments

+english

25th Jan 2017

More

The cell in real time

How to measure cells numbers directly in cell culture medium, without biological markers or internal sensors

+english

16th Jan 2017

More

Our roadmap for 2017 : development and one more location !

2016 ended very well for HCS Pharma, with a fundraising finalized with the regional funds of the French country...